# Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

> **NCT07321613** · — · COMPLETED · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 545 (actual)

## Conditions studied

- Hepatocellular Cancer (HCC)

## Interventions

- **DRUG:** Thalidomide (50mg)
- **DRUG:** carmofur
- **DRUG:** compound mylabris capsule
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT07321613
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321613, "Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07321613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*